- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00552058
Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease
10 de julio de 2018 actualizado por: UCB Pharma
Phase IIIb, Multinational, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-Tumor Necrosis Factor(TNF)-Alpha Monoclonal Antibody, Administered in Subjects With Moderately to Severely Active Crohn's Disease.
The primary objective of the study is to evaluate efficacy of certolizumab pegol in inducing clinical remission in patients with moderate to severe Crohn's disease as compared with placebo based on Crohn's Disease Activity Index (CDAI) score at Week 6.
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Intervencionista
Inscripción (Actual)
439
Fase
- Fase 3
Acceso ampliado
Disponible fuera del ensayo clínico.
Ver registro de acceso ampliado.
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
-
Berlin, Alemania
-
Frankfurt, Alemania
-
Freiburg, Alemania
-
Homburg, Alemania
-
Jena, Alemania
-
Kiel, Alemania
-
Munchen, Alemania
-
Ulm, Alemania
-
Wilhelmshaven, Alemania
-
-
-
-
-
Adelaide, Australia
-
Bankstown, Australia
-
Clayton, Australia
-
Fitzroy, Australia
-
Fremantle, Australia
-
Garran, Australia
-
-
New South Wales
-
Concord, New South Wales, Australia
-
-
Victoria
-
Box Hill, Victoria, Australia
-
Footscray, Victoria, Australia
-
Parkville, Victoria, Australia
-
-
-
-
-
Wien, Austria
-
-
-
-
-
Curitiba, Brasil
-
Goiania, Brasil
-
Porto Alegre, Brasil
-
Rio de Janeiro, Brasil
-
Santo-Andre, Brasil
-
Santos, Brasil
-
Sao Paulo, Brasil
-
-
MG
-
Belo-Horizonte, MG, Brasil
-
-
-
-
-
Bonheiden, Bélgica
-
Brussels, Bélgica
-
Gent, Bélgica
-
Leuven, Bélgica
-
Liege, Bélgica
-
Roeselare, Bélgica
-
-
-
-
-
Calgary, Canadá
-
-
Alberta
-
Edmonton, Alberta, Canadá
-
-
British Columbia
-
Kelowna, British Columbia, Canadá
-
-
Manitoba
-
Winnipeg, Manitoba, Canadá
-
-
Ontario
-
Hamilton, Ontario, Canadá
-
Kingston, Ontario, Canadá
-
London, Ontario, Canadá
-
Toronto, Ontario, Canadá
-
-
-
-
-
Hradec Kralove, Chequia
-
Hradek Kralove, Chequia
-
Praha 7, Chequia
-
Usti Nad Orlici, Chequia
-
Zlin, Chequia
-
-
-
-
-
Santiago, Chile
-
Vina del Mar, Chile
-
-
-
-
Alabama
-
Pell City, Alabama, Estados Unidos
-
-
Colorado
-
Colorado Springs, Colorado, Estados Unidos
-
Lakewood, Colorado, Estados Unidos
-
Littleton, Colorado, Estados Unidos
-
-
Florida
-
Hollywood, Florida, Estados Unidos
-
Jacksonville, Florida, Estados Unidos
-
New Port Richey, Florida, Estados Unidos
-
Winter Park, Florida, Estados Unidos
-
-
Illinois
-
Chicago, Illinois, Estados Unidos
-
-
Kentucky
-
Louisville, Kentucky, Estados Unidos
-
-
Louisiana
-
Metairie, Louisiana, Estados Unidos
-
Monroe, Louisiana, Estados Unidos
-
-
Maryland
-
Annapolis, Maryland, Estados Unidos
-
Towson, Maryland, Estados Unidos
-
-
Michigan
-
Chesterfield, Michigan, Estados Unidos
-
West Bloomfield, Michigan, Estados Unidos
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos
-
-
North Carolina
-
Raleigh, North Carolina, Estados Unidos
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos
-
Cleveland, Ohio, Estados Unidos
-
-
Pennsylvania
-
Lancaster, Pennsylvania, Estados Unidos
-
-
Tennessee
-
Germantown, Tennessee, Estados Unidos
-
-
Virginia
-
Norfolk, Virginia, Estados Unidos
-
-
Washington
-
Seattle, Washington, Estados Unidos
-
-
-
-
-
Tallin, Estonia
-
Tartu, Estonia
-
-
-
-
-
Kazan, Federación Rusa
-
Moscow, Federación Rusa
-
St. Petersburg, Federación Rusa
-
-
-
-
-
Mikkeli, Finlandia
-
-
-
-
-
Budapest, Hungría
-
Gyor, Hungría
-
Nagykanizsa, Hungría
-
Szeged, Hungría
-
Szombathely, Hungría
-
-
-
-
-
Beer Sheva, Israel
-
Haifa, Israel
-
Holon, Israel
-
Jerusalem, Israel
-
Kfar Saba, Israel
-
Petha Tikva, Israel
-
Rehovot, Israel
-
Tel Aviv, Israel
-
Zerifin, Israel
-
-
-
-
-
Bologna, Italia
-
Padova, Italia
-
Roma, Italia
-
-
-
-
-
Riga, Letonia
-
Valmiera, Letonia
-
-
-
-
-
Auckland, Nueva Zelanda
-
Christchurch, Nueva Zelanda
-
Hamilton, Nueva Zelanda
-
-
Auckland
-
Milford, Auckland, Nueva Zelanda
-
-
Wellington
-
Newton, Wellington, Nueva Zelanda
-
-
-
-
-
Czestochowa, Polonia
-
Lodz, Polonia
-
Warszawa, Polonia
-
Wroclaw, Polonia
-
-
-
-
-
Bucharest, Rumania
-
Cluj Napoca, Rumania
-
Constanta, Rumania
-
-
-
-
-
Dniepropetrovsk, Ucrania
-
Donetsk, Ucrania
-
Kiev, Ucrania
-
Kyiv, Ucrania
-
Lviv, Ucrania
-
Simferopol, Ucrania
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años a 75 años (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- male/female
- 18 - 75 years inclusive
- diagnosis of Crohn's disease confirmed
- moderate to severe disease activity (Crohn's Disease Activity Index (CDAI) 225 - 450)
- no previous treatment with anti-tumor necrosis factor (anti-TNF) medications
Exclusion Criteria:
- previous participation in a certolizumab pegol study
- general exclusion criteria as common for studies in this indication
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Certolizumab pegol
Certolizumab pegol 400 mg for subcutaneous (sc) injection
|
Certolizumab Pegol 400 mg CZP sc injection 2 x 1 mL CZP (200 mg/mL) at Week 0, 2, and 4
Otros nombres:
|
Comparador de placebos: Placebo
Placebo, saline solution for sc injection
|
Saline 0.9% sc injection 2 x 1 mL Placebo at Week 0, 2 and 4
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Percentage of Subjects in Clinical Remission at Week 6
Periodo de tiempo: Week 6
|
The percentage of subjects in clinical remission at Week 6 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 6
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Percentage of Subjects Achieving a Clinical Response at Week 6
Periodo de tiempo: Week 0, Week 6
|
The percentage of subjects achieving a clinical response at Week 6 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 6
|
Percentage of Subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week 6
Periodo de tiempo: Week 6
|
The percentage of subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) remission at Week 6 (IBDQ remission is defined as a total IBDQ score of 170 points or more).
The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.
|
Week 6
|
Change in Total Crohn's Disease Activity Index (CDAI) Score From Week 0 to Week 6
Periodo de tiempo: Week 0 to Week 6
|
The change in total Crohn's Disease Activity Index (CDAI) score from Week 0 to Week 6. CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0 to Week 6
|
Change in Harvey Bradshaw Index (HBI) Score From Week 0 to Week 6
Periodo de tiempo: Week 0 to Week 6
|
The change in Harvey Bradshaw Index (HBI) score from Week 0 to Week 6. HBI score consists of clinical parameters of general well-being (0 to 4), abdominal pain (0 to 3), number of liquid stools per day, abdominal mass (0 to 3), and complications (score 1 per item).
The first three items are scored for the previous day.
Lower scores indicated better well being.
|
Week 0 to Week 6
|
Percentage of Subjects in Clinical Remission at Week 2
Periodo de tiempo: Week 2
|
The percentage of subjects in clinical remission at Week 2 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 2
|
Percentage of Subjects in Clinical Remission at Week 4
Periodo de tiempo: Week 4
|
The percentage of subjects in clinical remission at Week 4 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 4
|
Percentage of Subjects Achieving a Clinical Response at Week 2
Periodo de tiempo: Week 0, Week 2
|
The percentage of subjects achieving a clinical response at Week 2 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 2
|
Percentage of Subjects Achieving a Clinical Response at Week 4
Periodo de tiempo: Week 0, Week 4
|
The percentage of subjects achieving a clinical response at Week 4 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 4
|
Change in Total Crohn's Disease Activity Index (CDAI) Score From Week 0 to Week 2
Periodo de tiempo: Week 0 to Week 2
|
The change in total Crohn's Disease Activity Index (CDAI) score from Week 0 to Week 2. CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0 to Week 2
|
Change in Total Crohn's Disease Activity Index (CDAI) Score From Week 0 to Week 4
Periodo de tiempo: Week 0, Week 4
|
The change in total Crohn's Disease Activity Index (CDAI) score from Week 0 to Week 4. CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 4
|
Percentage of Subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week 2
Periodo de tiempo: Week 2
|
The percentage of subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) remission at Week 2 (IBDQ remission is defined as a total IBDQ score of 170 points or more).
The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.
|
Week 2
|
Percentage of Subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week 4
Periodo de tiempo: Week 4
|
The percentage of subjects in Inflammatory Bowel Disease Questionnaire (IBDQ) remission at Week 4 (IBDQ remission is defined as a total IBDQ score of 170 points or more).
The IBDQ Global Score is the sum of 32 responses, each ranging from 0 to 7, thus the Global Score ranges from 0 to 224; a higher score indicating a better quality of life.
|
Week 4
|
Percentage of Subjects in Subgroup With Less Than 10 mg/L C-reactive Protein (CRP) at Entry Who Are in Clinical Remission at Week 6
Periodo de tiempo: Week 6
|
The percentage of subjects in the subgroup with less than 10 mg/L of C-reactive Protein (CRP) at Entry who are in clinical remission at Week 6 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 6
|
Percentage of Subjects in Subgroup With 10 mg/L or Greater C-reactive Protein (CRP) at Entry Who Are in Clinical Remission at Week 6
Periodo de tiempo: Week 6
|
The percentage of subjects in the subgroup with 10 mg/L or greater C-reactive Protein (CRP) at Entry in clinical remission at Week 6 (clinical remission is defined as a total Crohn's Disease Activity Index (CDAI) score of 150 points or less).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 6
|
Percentage of Subjects in Subgroup With Less Than 10 mg/L C-reactive Protein (CRP) at Entry Achieving a Clinical Response at Week 6
Periodo de tiempo: Week 0, Week 6
|
The percentage of subjects in the subgroup with less than 10 mg/L C-reactive Protein (CRP) at Entry achieving a clinical response at Week 6 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 6
|
Percentage of Subjects in Subgroup With 10 mg/L or Greater C-reactive Protein (CRP) at Entry Achieving a Clinical Response at Week 6
Periodo de tiempo: Week 0, Week 6
|
The percentage of subjects in the subgroup with 10 mg/L or greater C-reactive Protein (CRP) at Entry achieving a clinical response at Week 6 (clinical response is defined as at least a 100-point decrease from the Week 0 Crohn's Disease Activity Index (CDAI) score).
CDAI is used to quantify the symptoms of subjects with Crohn's disease.
A score of 150 points or below indicates clinical remission and a score above 450 points indicates extremely severe disease.
|
Week 0, Week 6
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Publicaciones Generales
- Sandborn WJ, Schreiber S, Feagan BG, Rutgeerts P, Younes ZH, Bloomfield R, Coteur G, Guzman JP, D'Haens GR. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol. 2011 Aug;9(8):670-678.e3. doi: 10.1016/j.cgh.2011.04.031. Epub 2011 May 13.
- Sandborn WJ, Melmed GY, McGovern DP, Loftus EV Jr, Choi JM, Cho JH, Abraham B, Gutierrez A, Lichtenstein G, Lee SD, Randall CW, Schwartz DA, Regueiro M, Siegel CA, Spearman M, Kosutic G, Pierre-Louis B, Coarse J, Schreiber S. Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study. Aliment Pharmacol Ther. 2015 Aug;42(3):330-42. doi: 10.1111/apt.13251. Epub 2015 Jun 1.
- Sandborn WJ, Lee SD, Randall C, Gutierrez A, Schwartz DA, Ambarkhane S, Kayhan C, Pierre-Louis B, Schreiber S, Lichtenstein GR. Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study. Aliment Pharmacol Ther. 2014 Oct;40(8):903-16. doi: 10.1111/apt.12930. Epub 2014 Aug 22.
Enlaces Útiles
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
1 de marzo de 2008
Finalización primaria (Actual)
1 de octubre de 2009
Finalización del estudio (Actual)
1 de noviembre de 2009
Fechas de registro del estudio
Enviado por primera vez
18 de octubre de 2007
Primero enviado que cumplió con los criterios de control de calidad
31 de octubre de 2007
Publicado por primera vez (Estimar)
1 de noviembre de 2007
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
9 de agosto de 2018
Última actualización enviada que cumplió con los criterios de control de calidad
10 de julio de 2018
Última verificación
1 de octubre de 2011
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- C87085
- 2007-001913-41 (Número EudraCT)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Enfermedad de Crohn
-
ProgenaBiomeReclutamientoEnfermedad de Crohn | Colitis de Crohn | Ileocolitis de Crohn | Gastritis de crohn | Jejunitis de Crohn | Duodenitis de Crohn | Esofagitis de Crohn | Crohn | Enfermedad de Crohn del íleon | Ileítis de Crohn | Recaída de la enfermedad de Crohn | Enfermedad de Crohn agravada | Enfermedad de Crohn en remisión | Enfermedad...Estados Unidos
-
Massachusetts General HospitalAmerican College of GastroenterologyAún no reclutandoEstimación de Riesgo Personalizada para la Enfermedad de Crohn (PRE-CD): Implementación y ViabilidadEnfermedades inflamatorias del intestino | Enfermedad de Crohn | Colitis de Crohn | Ileocolitis de Crohn | Gastritis de crohn | Jejunitis de Crohn | Duodenitis de Crohn | Esofagitis de CrohnEstados Unidos
-
Janssen-Cilag Ltd.ReclutamientoEnfermedad de Crohn fistulizante | Enfermedad de Crohn perianalPaíses Bajos, Estados Unidos, Bélgica, Corea, república de, Taiwán, Israel, Japón, Canadá, Hungría, Alemania, Grecia, Reino Unido, Australia, España, Arabia Saudita, Polonia, Pavo, Portugal, Chequia, Italia, Jordán, Francia
-
Groupe Hospitalier Paris Saint JosephTerminado
-
ViomeActivo, no reclutandoEnfermedad de Crohn | Colitis ulcerosa | Enfermedad de Crohn agravada | Enfermedad de Crohn en remisión | Intestino irritableEstados Unidos
-
S.L.A. Pharma AGTerminado
-
Agomab Spain S.L.ReclutamientoEnfermedad de Crohn fibrostenóticaEstados Unidos, Italia, Polonia, España, Dinamarca, Austria, Canadá, Alemania
-
AbbVieActivo, no reclutandoEnfermedad de Crohn (EC)Estados Unidos, Bélgica, Canadá, Chequia, Dinamarca, Francia, Alemania, Hungría, Israel, Italia, Países Bajos, Nueva Zelanda, Noruega, Polonia, Rumania, Eslovaquia, España, Reino Unido
-
University of Rome Tor VergataDesconocidoEnfermedad de Crohn | Ileocolitis de CrohnItalia
Ensayos clínicos sobre certolizumab pegol (CDP870, CZP)
-
UCB Japan Co. Ltd.TerminadoEnfermedad de CrohnJapón
-
UCB PharmaTerminadoArtritis ReumatoideDinamarca, Países Bajos, Polonia, Suecia
-
UCB Pharma SATerminadoEnfermedad de CrohnEstados Unidos, Australia, Austria, Bielorrusia, Bélgica, Bulgaria, Canadá, Chequia, Dinamarca, Estonia, Alemania, Hungría, Israel, Italia, Nueva Zelanda, Noruega, Polonia, Federación Rusa, Serbia, Singapur, Eslovenia, Sudáfrica, España, Ucrani...
-
UCB Pharma SATerminadoEnfermedad de CrohnEstados Unidos, Australia, Austria, Bielorrusia, Bélgica, Bulgaria, Chequia, Dinamarca, Estonia, Alemania, Hungría, Israel, Italia, Nueva Zelanda, Noruega, Polonia, Federación Rusa, Serbia, Singapur, Eslovenia, Sudáfrica, España, Ucrania, Cana... y más
-
UCB PharmaTerminado
-
UCB PharmaTerminadoEnfermedad de CrohnEstados Unidos, Alemania, Canadá
-
UCB PharmaTerminado
-
UCB Biopharma SRLTerminadoEspondiloartritis axial (axSpA) | Uveítis anterior (UA)Chequia, Alemania, Países Bajos, Polonia, España
-
Nathan Wei, MD, FACP, FACR:University of California, San DiegoTerminadoArtritis ReumatoideEstados Unidos
-
UCB BIOSCIENCES GmbHPPDTerminadoEnfermedad de CrohnFederación Rusa, Bélgica, Estados Unidos, Australia, Austria, Brasil, Canadá, Chequia, Estonia, Alemania, Hungría, Israel, Italia, Letonia, Nueva Zelanda, Polonia, Rumania, Ucrania